IceCure Medical (NASDAQ:ICCM) Cut to Sell at Wall Street Zen

IceCure Medical (NASDAQ:ICCM - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research report issued on Saturday.

Separately, HC Wainwright reiterated a "buy" rating and issued a $2.50 price target on shares of IceCure Medical in a research report on Thursday, May 29th.

IceCure Medical Stock Performance

Shares of ICCM stock traded down $0.01 during trading hours on Friday, reaching $1.03. 306,380 shares of the company's stock were exchanged, compared to its average volume of 485,529. IceCure Medical has a fifty-two week low of $0.48 and a fifty-two week high of $1.66. The stock has a market capitalization of $60.16 million, a P/E ratio of -3.66 and a beta of 0.31. The business has a fifty day moving average price of $1.02 and a 200-day moving average price of $1.17. The company has a quick ratio of 1.48, a current ratio of 1.89 and a debt-to-equity ratio of 0.02.

IceCure Medical (NASDAQ:ICCM - Get Free Report) last issued its earnings results on Wednesday, May 28th. The company reported ($0.06) EPS for the quarter, beating analysts' consensus estimates of ($0.08) by $0.02. IceCure Medical had a negative return on equity of 182.26% and a negative net margin of 467.37%. The business had revenue of $0.73 million during the quarter, compared to analyst estimates of $0.75 million. During the same period in the prior year, the company posted ($0.08) earnings per share. Analysts predict that IceCure Medical will post -0.28 EPS for the current fiscal year.

Institutional Trading of IceCure Medical

A hedge fund recently raised its stake in IceCure Medical stock. Geode Capital Management LLC increased its position in shares of IceCure Medical Ltd. (NASDAQ:ICCM - Free Report) by 58.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 40,453 shares of the company's stock after acquiring an additional 14,893 shares during the quarter. Geode Capital Management LLC owned about 0.07% of IceCure Medical worth $44,000 at the end of the most recent quarter. Institutional investors and hedge funds own 0.62% of the company's stock.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.